tbuckley/cabot-search huggingface dataset:
Network biology and artificial intelligence drive the understanding of the multidrug resistance phenotype in cancer
Authors: Beatriz Bueschbell, Ana Beatriz Caniceiro, Pedro M.S. Suzano, Miguel Machuqueiro, Nícia Rosário-Ferreira, Irina S. Moreira
Journal: Drug Resistance Updates (2022)

Globally with over 10 million deaths per year, cancer is the most transversal disease across countries, cultures, and ethnicities, affecting both developed and developing regions. Tumorigenesis is dynamically altered by distinct events and can be lethal when untreated. Despite the innovative therapeutics available, multidrug resistance (MDR) to chemotherapy remains the major hindrance to the success of cancer therapy. The multiple mechanisms by which cancer cells evade cell death are diverse, indicating that MDR involves complex interconnected biological networks. Molecular profiling is currently able to stratify cancer into its distinct subtypes and help identify the best therapeutics, leading to "translational systems medicine". Highly specialized methodologies are generating a large amount of "omics" data - including epigenetics, genomics, transcriptomics, proteomics, metabolomics, as well as pharmacogenomics. Many of the resulting databases store data in non-standard formats, which need to be converted, interpreted, and merged into readable formats. The latest development of artificial intelligence (AI) methodologies and tools, coupled with advancements in large-scale data management and powerful graphic processing computing units, potentiate the integration of these large data sources into relevant biological networks, which will enhance our understanding of cancer MDR. In this review, we revisit common MDR mechanisms and compile a list of the most relevant "omics" public databases. We highlight examples of AI methods that are now decisively contributing to clear advances in cancer research, such as identification of new drugs from large databases and prediction of relevant drug, target, and system properties. An overview of several freely available "ready-to-use" algorithms is also provided. The described molecular scale AI algorithms and tools will undoubtedly guide important improvements in efficiency and efficacy of traditional methods of cancer diagnostics and treatment.
Forthcoming BMJ theme issues (provisional dates and titles)
Journal: BMJ (2003)

patients to respond to, or to engage the public more widely through, for example, a citizens' jury or deliberative polling. ConclusionsPatients are willing to allow their information to be used for research purposes, but most want to be consulted first.Obtaining individual consent for registries and research studies using medical records presents logistical challenges that call for new approaches to consent, taking into account the varying needs of the public and the evolving uses of personal information in a broader context.We thank Sue Troyan for assistance with reviewing the transcripts and in the planning and execution of the survey.
Type 2 Diabetes, Glycemic Control, and Their Association With Dementia and Its Major Subtypes: Findings From the Swedish National Diabetes Register
Authors: Carlos A. Celis-Morales, Stefan Franzén, Katarina Eeg-Olofsson, Emma Nauclér, Ann-Marie Svensson, Soffia Gudbjornsdottir, Bjorn Eliasson, Naveed Sattar
Journal: Diabetes Care (2022)

OBJECTIVE Type 2 diabetes has been associated with high dementia risk. However, the links to different dementia subtypes is unclear. We examined to what extent type 2 diabetes is associated with dementia subtypes and whether such associations differed by glycemic control. RESEARCH DESIGN AND METHODS We used data from the Swedish National Diabetes Register and included 378,299 patients with type 2 diabetes and 1,886,022 control subjects matched for age, sex, and county randomly selected from the Swedish Total Population Register. The outcomes were incidence of Alzheimer disease, vascular dementia, and nonvascular dementia. The association of type 2 diabetes with dementia was stratified by baseline glycated hemoglobin (HbA1c) in patients with type 2 diabetes only. Cox regression was used to study the excess risk of outcomes. RESULTS Over the follow-up (median 6.8 years), dementia developed in 11,508 (3.0%) patients with type 2 diabetes and 52,244 (2.7%) control subjects. The strongest association was observed for vascular dementia, with patients with type 2 diabetes compared with control subjects having a hazard ratio [HR] of 1.34 (95% CI 1.28, 1.41). The association of type 2 diabetes with nonvascular dementia was more modest (HR 1.10 [95% CI 1.07, 1.13]). However, risk for Alzheimer disease was lower in patients with type 2 diabetes than in control subjects (HR 0.94 [95% CI 0.90, 0.99]). When the analyses were stratified by circulating concentrations of HbA1c, a dose-response association was observed. CONCLUSIONS The association of type 2 diabetes with dementia differs by subtypes of dementia. The strongest detrimental association is observed for vascular dementia. Moreover, patients with type 2 diabetes with poor glycemic control have an increased risk of developing vascular and nonvascular dementia.
Treatment patterns among patients with HAE-C1-INH: Interim analysis findings from US and Canada participants in the EMPOWER study
Authors: Dawn Goodyear, William Lumry, John Anderson, Remi Gagnon, Emily Brouwer, Tomas Andriotti, Kezhen Fei, Raffi Tachdjian, Ashley Yegin, Timothy Craig
Journal: Journal of Allergy and Clinical Immunology (2022)
Improved prediction of asthma exacerbations by measuring distal airway inflammation
Authors: Emmanouil Paraskakis, Evangelia Sarikloglou, Sotirios Fouzas, Paschalis Steiropoulos, Aggelos Tsalkidis, Andrew Bush
Journal: European Respiratory Journal (2022)

Introduction Partitioning parameters measured from exhaled nitric oxide, such as the alveolar concentration of nitric oxide ( C alvNO ), may provide better predictors of future asthma exacerbation than exhaled nitric oxide fraction at an expiratory flow rate of 50 mL·s −1 ( F ENO 50 ). We aimed to determine whether any partitioned nitric oxide parameters were more closely associated than F ENO 50 with subsequent asthma exacerbations. Methods 68 asthmatic children (mean± sd age 9.0±2.4 years) were followed prospectively (134 visits) and exacerbations were recorded. Childhood Asthma Control Test (cACT), spirometry, F ENO 50 , C alvNO , bronchial flux of nitric oxide ( J awNO ), transfer factor of nitric oxide ( D awNO ) and airway wall concentration of nitric oxide ( C awNO ) were measured. Results No exacerbation was recorded in 99 visits (Group 1) and an exacerbation was recorded in 35 visits (Group 2). The median (range) F ENO 50 , J awNO , C alvNO , D awNO and C awNO of Group 1 versus Group 2: 12.7 (4–209) versus 13.5 (3.8–149.9) ppb, 715 (10–12 799) versus 438 (40–7457) pL·s −1 , 3.4 (0.2–10.8) versus 5.2 (1.7–23.6) ppb, 38.3 (0.2–113.3) versus 38 (1.3–144.5) pL·s −1 ·ppb − 1 and 26.8 (4.1–2163) versus 29.9 (5.5–3054) ppb, respectively. Other than for C alvNO (p&lt;0.001), there was no difference between the two groups. C alvNO &gt;7 ppb predicted asthma exacerbation with specificity 90.9% and positive likelihood ratio (LR) 3.1. Conversely, C alvNO &lt;4 ppb excluded an exacerbation with sensitivity 71.4% and negative LR 0.48. An increase of C alvNO by 0.5 ppb between visits could also predict an exacerbation with sensitivity 92%, specificity 92%, positive LR 11.8 and negative LR 0.08. Conclusions Assessment of C alvNO improved prediction of subsequent exacerbation, highlighting the importance of distal inflammation in asthma outcomes in children.
From the Centers for Disease Control. National AIDS Information Clearinghouse
Journal: JAMA (1990)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Minimally invasive implantation and decreased inflammation reduce osteoinduction of biomaterial: Erratum
Authors: Zifan Zhao, Qin Zhao, Bin Gu, Chengcheng Yin, Kailun Shen, Hua Tang, Haibin Xia, Xiaoxin Zhang, Yanbing Zhao, Xiangliang Yang, Yufeng Zhang
Journal: Theranostics (2022)

[This corrects the article DOI: 10.7150/thno.39507.].
Walk the line
Authors: Michelle J Thompson
Journal: BMJ (2006)

and therapeutic interventions has now been incorporated in clinical guidelines.A few initial surveys have shown that these guidelines are being followed to some extent, but there is still room for improvement, especially in those countries and settings in which a large discrepancy exists between recommendations in guidelines and actual management in clinical practice.Measures should be taken to minimise this gap.Simply developing and publishing evidence based guidelines and subsequently disseminating these guidelines may not be effective enough to change practice.Implementation seems essential in changing clinical practice.Several trials have evaluated implementation of guidelines and its effect on patient and process outcomes. 25w8 These trials show modest effects at best.More intensive multifaceted interventions might be needed to achieve further progress in this area.We thank M A Pellikaan, a trainee general practitioner, for her help in getting the patients' stories.
Aggressive Lymphomas
Authors: Georg Lenz, Louis M. Staudt
Journal: New England Journal of Medicine (2010)

This review summarizes recent evidence concerning molecular changes in the commonest type of lymphoma, diffuse large-B-cell lymphoma. Detailed studies have revealed three subtypes, each with distinctive clinical and molecular features. The molecular dissection of these tumors is uncovering new possibilities for treatment, some of which are already in clinical trials.
Sex and genetic background define the metabolic, physiologic, and molecular response to protein restriction
Authors: Cara L Green, Heidi H Pak, Nicole E Richardson, Victoria Flores, Deyang Yu, Jay L Tomasiewicz, Sabrina N Dumas, Katherine Kredell, Jesse W Fan, Charlie Kirsh, Krittisak Chaiyakul, Michaela E Murphy, Reji Babygirija, Gregory A Barrett-Wilt, Joshua Rabinowitz, Irene M Ong, Cholsoon Jang, Judith Simcox, Dudley W Lamming
Journal: Cell Metabolism (2022)
Clinical Trial Experience With a New Pollen Sampling Network In The US
Authors: Jonathan Bernstein, Jonathan Matz, Gary Steven, William Greisner, David Cypcar, Arthur Fost, Richard Powell, Chris Smith, Markus Berger, Uwe Berger, Lukas Dirr, Maximilian Bastl, Johannes Bouchal, Helena Pujol, Marietta Krebs, Oliver Armfield, Lawrence DuBuske, Pieter-Jan de Kam
Journal: Journal of Allergy and Clinical Immunology (2022)
Impact Of Wildfire On Patients With Respiratory Allergy In An Urban Setting
Authors: Laura Paola Escamilla Luna, Cindy de Lira-Quezada, Sandra González-Díaz, Sandra Cantú-Sánchez, Miriam Bárcenas-Aguilar, José Mares-Gil, Rosalaura Villarreal Gonzalez
Journal: Journal of Allergy and Clinical Immunology (2022)
TCT-749 Worldwide every-day practice registry assessing the Xposition S Self-Apposing stent in challenging lesions with vessel diameter variance (SIZING registry)
Authors: Floris Kauer, Marcus Siry, Daniel Weilenmann, Adam Sukiennik, Samer Somi, David Bouchez, Alexander Ijsselmuiden
Journal: Journal of the American College of Cardiology (2017)
World Hepatitis Day — July 28, 2019
Journal: MMWR Morbidity and Mortality Weekly Report (2019)

World Hepatitis Day, observed each year on July 28, was established to raise awareness and promote understanding of viral hepatitis around the world. The theme of this year's World Hepatitis Day is "Invest in Eliminating Hepatitis," underscoring the need to increase commitment for hepatitis response. In 2015, an estimated 257 million persons were living with hepatitis B and 71 million with hepatitis C worldwide (1).
When I use a word . . . . Vaccination—rights and duties
Authors: Jeffrey K Aronson
Journal: BMJ (2022)

A previous benefit:harm balance analysis suggested that the UK government’s declared policy of dismissing frontline healthcare workers if they continued to be unvaccinated against SARS-CoV2 would bring more harm to the NHS than benefit. This has proved to be so, and the policy has been withdrawn, a welcome move. However, the problem remains that over 5% of the frontline workforce are still unvaccinated, putting patients at increased risk of infection. Those who refuse to be vaccinated should ask themselves whether their desire to exercise their right not to be vaccinated, for any reason other than a medical contraindication, is more important than their duty of care to their patients. Both vaccinated and unvaccinated healthcare workers, out of respect for their patients, could consider wearing badges declaring their vaccination status, so that patients, knowing who was taking care of them, might decide whether they want to have a conversation about it.
Intravital three-photon microscopy allows visualization over the entire depth of mouse lymph nodes
Authors: Kibaek Choe, Yusaku Hontani, Tianyu Wang, Eric Hebert, Dimitre G. Ouzounov, Kristine Lai, Ankur Singh, Wendy Béguelin, Ari M. Melnick, Chris Xu
Journal: Nature Immunology (2022)
UROLOGY
Authors: Bernard R. Sears
Journal: JAMA (1966)

The major event of the period under review is the publication of the second edition of Campbell's<i>Urology</i>(3 vols, Saunders, 1963, $90). So comprehensive and authoritative a work has an importance greater than the sum of its contents. As the only American encyclopedia on the subject, it plays a definitive role, and helps to define what urology is. T. W. Stamey's observations, in his book review of this second edition, deserve special notice. Stamey called for a "unitary approach" to the genitourinary system that would close the breach between "those physicians who deal with the area from the calyces to the urethral meatus (urologists) and those who know the urinary tract only from the capsule of the kidney to the calyces (internists and renal physiologists)." Had Stamey grounds to hope for a change? Had he perceived a new impulse? With the development of renal transplantation and the surgery of
Queries and Minor Notes.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Frequency and patterns of editorial rejections (rejections without peer review) across medical journals
Authors: Vishnu Harikumar, Kelly A. Reynolds, Rachel E. Christensen, Hoi Ting Wan, Rachael Winner, Sarah A. Ibrahim, Bianca Y. Kang, Denis Fouque, Emily Poon, Dirk M. Elston, Murad Alam
Journal: Journal of the American Academy of Dermatology (2022)
TCT-171 A First-in-Man Study of the Firesorb Sirolimus Target-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease (FUTURE-I): 3-Year Clinical and Imaging Outcomes
Authors: Lei Song, Changdong Guan, Zhongwei Sun, Run-Lin Gao, Bo Xu
Journal: Journal of the American College of Cardiology (2019)
Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan
Authors: Yuki Takumoto, Yuriko Sasahara, Hiroto Narimatsu, Manabu Akazawa
Journal: JAMA Network Open (2022)

Various first-line chemotherapy treatment regimens for patients with metastatic pancreatic cancer have been approved in Japan, including gemcitabine (GEM); fluorouracil, leucovorin, irinotecan, and oxaliplatin combination (FOLFIRINOX); GEM plus albumin-bound paclitaxel (GEM+NPTX), and S-1 (tegafur + gimeracil + oteracil). However, direct comparisons of these chemotherapy regimens are limited.To assess the short-term and long-term outcomes associated with first-line chemotherapy regimens for metastatic pancreatic cancer compared with chemotherapy regimens recommended in Japanese guidelines.In this systematic review and network meta-analysis, the bibliographic databases PubMed, Cochrane Library, and Web of Science, as well as medical journals published between January 1, 2002, and December 31, 2018, were searched for clinical trials comparing chemotherapy regimens.Randomized 2-arm clinical trials evaluating first-line chemotherapy for advanced or metastatic pancreatic cancer were included.The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions was followed for data abstractions. Data were pooled using a random-effects model. The SIGN 50 Quality Assessment Instrument was used to assess the risk of bias and overall study quality of the selected trials.The primary end point was overall survival (OS), and the secondary end point was progression-free survival (PFS) compared with GEM for first-line chemotherapy for metastatic pancreatic cancer. The Kaplan-Meier curve of GEM from the literature and the estimated hazard ratios (HRs) were used to model the long-term associations to calculate the area under the curve (AUC) (person-months) for OS and PFS of each chemotherapy. Sensitivity analyses with multiple functional models were conducted to confirm the long-term estimations.A total of 22 regimens (25 studies) for OS and a total of 18 regimens (21 studies) for PFS were identified from literature. The total number of participants was 10 186, with 5856 male (57.5%) and 4330 female (42.5%). The FOLFIRINOX and GEM+NPTX regimens were associated with reduction in the risk of death, with an HR of 0.57 (95% CI, 0.41-0.79) and 0.72 (95% CI, 0.55-0.95) compared with GEM, respectively. The curve estimation also showed that FOLFIRINOX had the largest AUC for survival at 15.49 person-months (range, 13.84-15.51 person-months), followed by GEM+NPTX with 12.36 person-months (range, 10.98-12.59 person-months), GEM+ERLO with 10.84 person-months (range, 9.66-11.23 person-months), S-1 with 8.44 person-months (range, 8.26-9.74 person-months), and GEM with 8.10 person-months (range, 7.93-9.38 person-months).The results of this network meta-analysis support the relative short-term and long-term outcomes associated with first-line chemotherapy for metastatic pancreatic cancer used clinically in Japan.
Keyword Index – Volumes 67+68
Journal: Cardiovascular Research (2005)

Volumes 67 + 68 Acetylcholine (67) 613 Acidosis (68) 366 Actin cytoskeleton (68) 26 a-Actinin (67) 225 Action potential (67) 459 Action potential duration (67) 77 Adenosine (67) 124 Adiponectin (67) 705 h-adrenergic stimulation (68) 366 a 1 -Adrenoreceptor (67) 699 Adult stem cells (68) 394 Aging (68) 355 Aldosterone (67) 97 Alternative splicing (68) 197 ANF (67) 583 Angiogenesis (67) 30, (68) 144, (68) 235, (68) 299, (68) 307 Angioplasty/coronary intervention (68) 493 Angiostensin system (67) 208 Angiotensin (67) 97, (67) 208, (67) 689 Angiotensin II (67) 50 Animal models (68) 415 Annexin V (68) 37 Antiarrhythmia agents (67) 69 Antibody (68) 249 Antihypertensive/diuretic agents (68) 118 AP-1 (67) 87 Apoptosis (67) 21, (67) 87, (68) 355 Arachidonic acid (68) 18 Arrhythmia (67) 77, (67) 367, (67) 467, (67) 529, (67) 561, (67) 655, (68) 433, (68) 441 Arrhythmia (mechanism) (67) 274, (67) 510 Arrhythmia (mechanisms) (67) 414, (67) 487, (67) 520, (67) 647, (68) 204 Arrhythmia mechanisms (67) 548 Arrhythmias (67) 388, (67) 397, (67) 426, (67) 438, (67) 498 Arteries (67) 208, (67) 548, (68) 415 Atherosclerosis (67) 11, (67) 151, (67) 317, (67) 333, (67) 714, (68) 128 Atrial fibrillation (67) 357 Atrial function (67) 274, (68) 8 Atrium (67) 69 Autoimmunity (68) 278 Autonomic nervous system (67) 283, (67) 736 Auxilliary subunits (67) 448 Balloon dilation (68) 136 Barrier function (68) 26 Blood flow (68) 318 Blood pressure (67) 208 Bone marrow-derived cell (68) 387 Ca-channel (67) 198, (67) 216, (67) 379, (67) 624 Calcium (67) 161, (67) 291, (67) 613, (68) 8 Calcium (cellular) (67) 308, (67) 636, (67) 667, (68) 65, (68) 75, (68) 204 Calcium channel (68) 197 Capacitative Ca 2+ entry (68) 56 Cardiac hypertrophy (67) 604, (68) 224 Cardiac memory (68) 259 Cardiac muscle (67) 291 Cardiac myocytes (67) 448, (68) 464 Cardiac regeneration (68) 394 Cardiac remodeling (67) 689 Cardiomyocyte (67) 161 Cardiomyocytes (67) 87, (67) 561, (68) 37, (68) 387 Cardiomyopathic hamster (67) 678 Cardiomyopathy (67) 539, (68) 213, (68) 355 Cardiovascular (68) 197 Cardiovascular surgery (67) 326 Catecholamines (67) 613 Caveolae (68) 128 Cell adhesion molecules (67) 448 Cell communication (67) 539, (68) 37 Cell culture (68) 75 Cell cycle (68) 483 Cell death (67) 21 Cell differentiation (67) 116, (67) 245 Cell proliferation (68) 47 Cell therapy (68) 307 Cell transplantation (67) 301 cGMP (68) 268 Channel physiology (67) 448 Chemokines (68) 278 CHF (68) 299 Cholesterol (68) 425 Chronic heart failure (68) 376 Cocaine (67) 699 Collagen (67) 50 Collateral circulation (68) 144 Computer modeling (67) 256 Conduction (block) (67) 367 Conduction velocity (67) 77 Congenital defects (67) 467 Connexin (67) 234 Contractile function (67) 161, (67) 216, (67) 225, (67) 636, (68) 307, (68) 327, (68) 464 contractility (68) 98 Contractility (67) 613 Contraction (67) 723 Coupling factor 6 (67) 134 C-reactive protein (68) 47 CREB (68) 259 Cyclic stretch (68) 405 Cyclooxygenase-2 (67) 723 CYP (68) 18 cytokines (68)
Robust genome and RNA editing via CRISPR nucleases in PiggyBac systems
Authors: Yuqian Jiang, Rachel Catherine Hoenisch, Yun Chang, Xiaoping Bao, Craig E. Cameron, Xiaojun Lance Lian
Journal: Bioactive Materials (2022)

CRISPR/Cas-mediated genome editing in human pluripotent stem cells (hPSCs) offers unprecedented opportunities for developing